GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals has sent a postal ballot notice to shareholders seeking their approval for the appointment of Mr. Ronojit Biswas (DIN 07684843) as a Whole-time Director and Chief Financial Officer of the company. His appointment is for a 3-year term, effective from 1st April 2026 to 31st March 2029. Mr. Biswas has over 25 years of experience within GSK across India, Vietnam, Singapore, Brazil, and the UK, and most recently served as Senior Finance Director – Global Product Strategy based in Singapore. His compensation package includes a basic salary of up to Rs. 16,00,000 per month, performance bonus of up to 100% of basic salary, long-term incentives, perquisites up to 2x annual salary, and a sign-on bonus of Rs. 20 lakhs. The e-voting window is open from 9th March 2026 to 8th April 2026, with results to be announced on or before 10th April 2026.
This is a routine governance item seeking shareholder approval for a senior leadership change. The resolution requires a simple majority to pass and is unlikely to materially affect the stock price, though it confirms continuity in the CFO position with an internal GSK candidate.